Kenneth J Pienta

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4377177/publications.pdf

Version: 2024-02-01

570	63,713	870 117	1006 236
papers	citations	h-index	g-index

600	600	600	59052
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer. Science, 2005, 310, 644-648.	6.0	3,541
2	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	13.5	2,660
3	The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 2002, 419, 624-629.	13.7	2,411
4	The mutational landscape of lethal castration-resistant prostate cancer. Nature, 2012, 487, 239-243.	13.7	2,128
5	Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2008, 14, 6302-6309.	3.2	1,975
6	Delineation of prognostic biomarkers in prostate cancer. Nature, 2001, 412, 822-826.	13.7	1,551
7	Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nature Genetics, 2013, 45, 1446-1451.	9.4	925
8	Integrative molecular concept modeling of prostate cancer progression. Nature Genetics, 2007, 39, 41-51.	9.4	837
9	Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases. Cancer Research, 2004, 64, 9209-9216.	0.4	816
10	Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Research, 2002, 62, 1832-7.	0.4	768
11	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature, 2007, 448, 595-599.	13.7	743
12	Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell, 2005, 8, 393-406.	7.7	731
13	Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. Cancer Discovery, 2011, 1, 487-495.	7.7	725
14	Targeting the tumour stroma to improve cancer therapy. Nature Reviews Clinical Oncology, 2018, 15, 366-381.	12.5	719
15	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. JAMA Oncology, 2020, 6, 650.	3.4	696
16	Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nature Genetics, 2013, 45, 180-185.	9.4	662
17	Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3933-3938.	3.3	641
18	CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer and Metastasis Reviews, 2010, 29, 709-722.	2.7	633

#	Article	IF	Citations
19	Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. Journal of Clinical Investigation, 2011, 121, 1298-1312.	3.9	628
20	Identification of Targetable FGFR Gene Fusions in Diverse Cancers. Cancer Discovery, 2013, 3, 636-647.	7.7	614
21	The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nature Genetics, 2013, 45, 1392-1398.	9.4	601
22	A Hierarchical Network of Transcription Factors Governs Androgen Receptor-Dependent Prostate Cancer Growth. Molecular Cell, 2007, 27, 380-392.	4.5	598
23	Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument. Urology, 1997, 50, 920-928.	0.5	595
24	Autoantibody Signatures in Prostate Cancer. New England Journal of Medicine, 2005, 353, 1224-1235.	13.9	581
25	Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E854-63.	3.3	576
26	Î±-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer. JAMA - Journal of the American Medical Association, 2002, 287, 1662.	3.8	565
27	Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncology, The, 2009, 10, 233-239.	5.1	558
28	Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study. Science Translational Medicine, 2011, 3, 111ra121.	5.8	531
29	Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell, 2017, 32, 474-489.e6.	7.7	483
30	TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer. Cancer Research, 2006, 66, 8337-8341.	0.4	475
31	CCL2 and Interleukin-6 Promote Survival of Human CD11b+ Peripheral Blood Mononuclear Cells and Induce M2-type Macrophage Polarization. Journal of Biological Chemistry, 2009, 284, 34342-34354.	1.6	474
32	The Role of CXCR7/RDC1 as a Chemokine Receptor for CXCL12/SDF-1 in Prostate Cancer. Journal of Biological Chemistry, 2008, 283, 4283-4294.	1.6	412
33	Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. Journal of Cellular Biochemistry, 2003, 89, 462-473.	1.2	405
34	Galectin-3 Induces Endothelial Cell Morphogenesis and Angiogenesis. American Journal of Pathology, 2000, 156, 899-909.	1.9	402
35	Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer. Cancer Cell, 2011, 19, 664-678.	7.7	397
36	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395

#	Article	IF	Citations
37	Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer. Clinical Cancer Research, 2006, 12, 1665-1671.	3.2	387
38	Evolution of cooperation among tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 13474-13479.	3.3	385
39	Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. Journal of Clinical Oncology, 2017, 35, 2149-2156.	0.8	371
40	Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget, 2016, 7, 27067-27084.	0.8	367
41	Risk Factors for Prostate Cancer. Annals of Internal Medicine, 1993, 118, 793.	2.0	356
42	Skeletal Localization and Neutralization of the SDF-1(CXCL12)/CXCR4 Axis Blocks Prostate Cancer Metastasis and Growth in Osseous Sites In Vivo. Journal of Bone and Mineral Research, 2004, 20, 318-329.	3.1	345
43	Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nature Communications, 2013, 4, 1795.	5.8	342
44	Global Gene Expression Profiling of Circulating Tumor Cells. Cancer Research, 2005, 65, 4993-4997.	0.4	328
45	The Current State of Hormonal Therapy for Prostate Cancer. Ca-A Cancer Journal for Clinicians, 2002, 52, 154-179.	157.7	323
46	A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome. Cancer Research, 2007, 67, 10657-10663.	0.4	308
47	Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor RegressionIn vivo. Cancer Research, 2007, 67, 9417-9424.	0.4	305
48	Classifying the evolutionary and ecological features of neoplasms. Nature Reviews Cancer, 2017, 17, 605-619.	12.8	303
49	Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Investigational New Drugs, 2013, 31, 760-768.	1.2	297
50	Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis. American Journal of Surgical Pathology, 2002, 26, 312-319.	2.1	294
51	Cross-Species Regulatory Network Analysis Identifies a Synergistic Interaction between FOXM1 and CENPF that Drives Prostate Cancer Malignancy. Cancer Cell, 2014, 25, 638-651.	7.7	293
52	Randomized clinical trial of a family intervention for prostate cancer patients and their spouses. Cancer, 2007, 110, 2809-2818.	2.0	283
53	Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Modern Pathology, 2007, 20, 538-544.	2.9	281
54	Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. Biomaterials, 2009, 30, 3020-3027.	5.7	274

#	Article	IF	Citations
55	GAS6/AXL Axis Regulates Prostate Cancer Invasion, Proliferation, and Survival in the Bone Marrow Niche. Neoplasia, 2010, 12, 116-IN4.	2.3	263
56	Characterization of TMPRSS2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer. Cancer Research, 2008, 68, 3584-3590.	0.4	249
57	The biology and treatment of oligometastatic cancer. Oncotarget, 2015, 6, 8491-8524.	0.8	243
58	Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment. Molecular Cancer, 2019, 18, 94.	7.9	237
59	Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2117-2136.	3.3	234
60	CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine and Growth Factor Reviews, 2010, 21, 41-48.	3.2	232
61	Transcription Factors OVOL1 and OVOL2 Induce the Mesenchymal to Epithelial Transition in Human Cancer. PLoS ONE, 2013, 8, e76773.	1.1	229
62	CCL2 is a Potent Regulator of Prostate Cancer Cell Migration and Proliferation. Neoplasia, 2006, 8, 578-586.	2.3	219
63	Annexin II/Annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. Journal of Cellular Biochemistry, 2008, 105, 370-380.	1.2	215
64	Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nature Reviews Urology, 2017, 14, 15-25.	1.9	210
65	Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Research, 2003, 63, 3805-11.	0.4	209
66	Multiple Roles of Chemokine (C-C Motif) Ligand 2 in Promoting Prostate Cancer Growth. Journal of the National Cancer Institute, 2010, 102, 522-528.	3.0	207
67	Preferential Adhesion of Prostate Cancer Cells to a Human Bone Marrow Endothelial Cell Line. Journal of the National Cancer Institute, 1998, 90, 118-123.	3.0	203
68	CCL2 as an Important Mediator of Prostate Cancer Growth In Vivo through the Regulation of Macrophage Infiltration. Neoplasia, 2007, 9, 556-562.	2.3	203
69	Cancer stem cells and their role in metastasis. , 2013, 138, 285-293.		203
70	Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology, 1999, 53, 260-266.	0.5	199
71	The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia, 2008, 22, 941-950.	3.3	192
72	Treatment-Dependent Androgen Receptor Mutations in Prostate Cancer Exploit Multiple Mechanisms to Evade Therapy. Cancer Research, 2009, 69, 4434-4442.	0.4	190

#	Article	IF	Citations
73	Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group. Journal of Clinical Oncology, 2004, 22, 537-556.	0.8	189
74	The Role of Î±vÎ²3 in Prostate Cancer Progression. Neoplasia, 2002, 4, 191-194.	2.3	188
75	Living With Prostate Cancer: Patients' and Spouses' Psychosocial Status and Quality of Life. Journal of Clinical Oncology, 2007, 25, 4171-4177.	0.8	188
76	The Chemokine CCL2 Increases Prostate Tumor Growth and Bone Metastasis through Macrophage and Osteoclast Recruitment. Neoplasia, 2009, 11, 1235-1242.	2.3	186
77	A structural analysis of the role of the nuclear matrix and DNA loops in the organization of the nucleus and chromosome. Journal of Cell Science, 1984, 1984, 123-135.	1.2	184
78	A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with ¹⁸ F-DCFPyL in Prostate Cancer Patients (OSPREY). Journal of Urology, 2021, 206, 52-61.	0.2	180
79	Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer and Metastasis Reviews, 2001, 20, 333-349.	2.7	179
80	Bone Turnover Mediates Preferential Localization of Prostate Cancer in the Skeleton. Endocrinology, 2005, 146, 1727-1736.	1.4	174
81	Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Human Molecular Genetics, 2004, 13, 1303-1313.	1.4	171
82	Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Molecular Cancer Therapeutics, 2008, 7, 2192-2202.	1.9	171
83	Stromal factors involved in prostate carcinoma metastasis to bone. Cancer, 2003, 97, 739-747.	2.0	168
84	Expression and activation of Î±vÎ²3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate, 2007, 67, 61-73.	1.2	167
85	Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation. Journal of Visualized Experiments, 2016, , .	0.2	166
86	A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology, 1998, 52, 257-260.	0.5	164
87	Mechanical Entrapment Is Insufficient and Intercellular Adhesion Is Essential for Metastatic Cell Arrest in Distant Organs. Neoplasia, 2005, 7, 522-527.	2.3	160
88	Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests. JAMA Oncology, 2018, 4, 868.	3.4	160
89	E-cadherin expression in prostate cancer: A broad survey using high-density tissue microarray technology. Human Pathology, 2001, 32, 690-697.	1.1	159
90	Phase II Trial of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Hormone-Refractory Prostate Cancer. Journal of Clinical Oncology, 1999, 17, 1664-1664.	0.8	158

#	Article	IF	Citations
91	Coupling the modules of EMT and stemness: A tunable â€˜stemness windowâ€™ model. Oncotarget, 2015, 6, 25161-25174.	0.8	157
92	CCL2 Protects Prostate Cancer PC3 Cells from Autophagic Death via Phosphatidylinositol 3-Kinase/AKT-dependent Survivin Up-regulation. Journal of Biological Chemistry, 2008, 283, 25057-25073.	1.6	156
93	Mechanisms of cancer cell metastasis to the bone: a multistep process. Future Oncology, 2011, 7, 1285-1297.	1.1	154
94	APC/CTNNB1 (?-catenin) pathway alterations in human prostate cancers. Genes Chromosomes and Cancer, 2002, 34, 9-16.	1.5	152
95	Nuclear structure and the three-dimensional organization of DNA. Journal of Cellular Biochemistry, 1991, 47, 289-299.	1.2	151
96	Glycolysis is the primary bioenergetic pathway for cell motility and cytoskeletal remodeling in human prostate and breast cancer cells. Oncotarget, 2015, 6, 130-143.	0.8	151
97	Ecological Therapy for Cancer: Defining Tumors Using an Ecosystem Paradigm Suggests New Opportunities for Novel Cancer Treatments. Translational Oncology, 2008, 1, 158-164.	1.7	150
98	Axl as a mediator of cellular growth and survival. Oncotarget, 2014, 5, 8818-8852.	0.8	150
99	MIM, a Potential Metastasis Suppressor Gene in Bladder Cancer. Neoplasia, 2002, 4, 291-294.	2.3	148
100	Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Research, 2011, 21, 47-55.	2.4	148
101	Circulating microRNA Profiling Identifies a Subset of Metastatic Prostate Cancer Patients with Evidence of Cancer-Associated Hypoxia. PLoS ONE, 2013, 8, e69239.	1.1	147
102	Advances in Prostate Cancer Chemotherapy: A New Era Begins. Ca-A Cancer Journal for Clinicians, 2005, 55, 300-318.	157.7	146
103	Overexpression, Amplification, and Androgen Regulation of TPD52 in Prostate Cancer. Cancer Research, 2004, 64, 3814-3822.	0.4	145
104	The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy. Ca-A Cancer Journal for Clinicians, 2007, 57, 225-241.	157.7	145
105	A Destructive Cascade Mediated by CCL2 Facilitates Prostate Cancer Growth in Bone. Cancer Research, 2009, 69, 1685-1692.	0.4	144
106	Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20111-20116.	3.3	144
107	A Glycolytic Mechanism Regulating an Angiogenic Switch in Prostate Cancer. Cancer Research, 2007, 67, 149-159.	0.4	140
108	Therapeutic Targeting of SPINK1-Positive Prostate Cancer. Science Translational Medicine, 2011, 3, 72ra17.	5.8	140

#	Article	IF	Citations
109	Polarization of Prostate Cancer-associated Macrophages Is Induced by Milk Fat Globule-EGF Factor 8 (MFG-E8)-mediated Efferocytosis. Journal of Biological Chemistry, 2014, 289, 24560-24572.	1.6	140
110	Erythropoietin Couples Hematopoiesis with Bone Formation. PLoS ONE, 2010, 5, e10853.	1.1	138
111	Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype. Journal of Clinical Oncology, 2005, 23, 8232-8241.	0.8	135
112	Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry, 2004, 62A, 46-53.	1.8	131
113	The Tissue Matrix: Cell Dynamics and Hormone Action*. Endocrine Reviews, 1990, 11, 399-417.	8.9	129
114	Dickkopfâ€1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate, 2008, 68, 1396-1404.	1.2	127
115	Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987. Urology, 1995, 45, 93-101.	0.5	122
116	Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigenâ€“Targeted PET Imaging: PSMA-RADS Version 1.0. Journal of Nuclear Medicine, 2018, 59, 479-485.	2.8	122
117	Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis. Journal of Experimental Medicine, 2019, 216, 2883-2899.	4.2	122
118	The current state of preclinical prostate cancer animal models. Prostate, 2008, 68, 629-639.	1.2	121
119	OVOL guides the epithelial-hybrid-mesenchymal transition. Oncotarget, 2015, 6, 15436-15448.	0.8	121
120	The evolving biology and treatment of prostate cancer. Journal of Clinical Investigation, 2007, 117, 2351-2361.	3.9	119
121	Cooperation among cancer cells: applying game theory to cancer. Nature Reviews Cancer, 2019, 19, 110-117.	12.8	118
122	Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance. Prostate, 2019, 79, 1489-1497.	1.2	116
123	The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia, 2002, 4, 191-4.	2.3	115
124	384 hanging drop arrays give excellent Zâ€factors and allow versatile formation of coâ€culture spheroids. Biotechnology and Bioengineering, 2012, 109, 1293-1304.	1.7	114
125	Correlation of nuclear morphometry with progression of breast cancer. Cancer, 1991, 68, 2012-2016.	2.0	113
126	Identification of Leukocyte E-Selectin Ligands, P-Selectin Glycoprotein Ligand-1 and E-Selectin Ligand-1, on Human Metastatic Prostate Tumor Cells. Cancer Research, 2005, 65, 5750-5760.	0.4	112

#	Article	IF	Citations
127	Common Structural and Epigenetic Changes in the Genome of Castration-Resistant Prostate Cancer. Cancer Research, 2012, 72, 616-625.	0.4	111
128	Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19491-19496.	3.3	109
129	GAS6 Receptor Status Is Associated with Dormancy and Bone Metastatic Tumor Formation. PLoS ONE, 2013, 8, e61873.	1.1	109
130	PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMAâ€“targeted PET Imaging Studies. European Urology, 2018, 73, 485-487.	0.9	108
131	Micro-ring structures stabilize microdroplets to enable long term spheroid culture in 384 hanging drop array plates. Biomedical Microdevices, 2012, 14, 313-323.	1.4	106
132	Regulation of Prostate Cancer Progression by Galectin-3. American Journal of Pathology, 2009, 174, 1515-1523.	1.9	104
133	Characterization of Phosphoglycerate Kinase-1 Expression of Stromal Cells Derived from Tumor Microenvironment in Prostate Cancer Progression. Cancer Research, 2010, 70, 471-480.	0.4	104
134	Integrative Analysis of Genomic Aberrations Associated with Prostate Cancer Progression. Cancer Research, 2007, 67, 8229-8239.	0.4	103
135	DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells, Which Promotes Prostate Cancer Metastasis. Neoplasia, 2016, 18, 553-566.	2.3	103
136	Metastatic prostate cancer remains incurable, why?. Asian Journal of Urology, 2019, 6, 26-41.	0.5	103
137	Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. Journal of Clinical Investigation, 2017, 128, 248-266.	3.9	103
138	TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis. Cancer Research, 2017, 77, 3181-3193.	0.4	102
139	A Feasibility Study Evaluating the Functional Diffusion Map as a Predictive Imaging Biomarker for Detection of Treatment Response in a Patient with Metastatic Prostate Cancer to the Bone. Neoplasia, 2007, 9, 1003-1011.	2.3	101
140	Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4762-9.	3.3	99
141	Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer and Prostatic Diseases, 2018, 21, 539-548.	2.0	99
142	Inhibition of Prostate Cancer Growth by Estramustineand Etoposide: Evidence For Interaction at the Nuclear Matrix. Journal of Urology, 1993, 149, 1622-1625.	0.2	98
143	Decreased galectin-3 expression in prostate cancer. Prostate, 2000, 44, 118-123.	1.2	98
144	TBK1 Regulates Prostate Cancer Dormancy through mTOR Inhibition. Neoplasia, 2013, 15, 1064-1074.	2.3	97

#	Article	IF	Citations
145	Characterization of extracellular vesicles and synthetic nanoparticles with four orthogonal singleâ€particle analysis platforms. Journal of Extracellular Vesicles, 2021, 10, e12079.	5.5	97
146	Comprehensive evaluation of methods for small extracellular vesicles separation from human plasma, urine and cell culture medium. Journal of Extracellular Vesicles, 2020, 10, e12044.	5.5	97
147	The Cancer Diaspora: Metastasis beyond the Seed and Soil Hypothesis. Clinical Cancer Research, 2013, 19, 5849-5855.	3.2	95
148	Hypoxia Stabilizes GAS6/Axl Signaling in Metastatic Prostate Cancer. Molecular Cancer Research, 2012, 10, 703-712.	1.5	93
149	Review of the role of androgenic hormones in the epidemiology of benign prostatc hyperplasia and prostate cancer. Urology, 1994, 43, 892-899.	0.5	92
150	A phase ii trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology, 1997, 50, 401-407.	0.5	92
151	A phased strategy to differentiate human CD14⁺monocytes into classically and alternatively activated macrophages and dendritic cells. BioTechniques, 2016, 61, 33-41.	0.8	92
152	Dynamic process of prostate cancer metastasis to bone. Journal of Cellular Biochemistry, 2004, 91, 706-717.	1.2	91
153	Nuclear-Cytoskeletal interactions: Evidence for physical connections between the nucleus and cell periphery and their alteration by transformation. Journal of Cellular Biochemistry, 1992, 49, 357-365.	1.2	90
154	A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology, 2002, 60, 760-765.	0.5	90
155	Tumor expressed PTHrP facilitates prostate cancerâ€induced osteoblastic lesions. International Journal of Cancer, 2008, 123, 2267-2278.	2.3	90
156	Single cell trapping in larger microwells capable of supporting cell spreading and proliferation. Microfluidics and Nanofluidics, 2010, 8, 263-268.	1.0	90
157	Galectin-3 as a Potential Therapeutic Target in Tumors Arising from Malignant Endothelia. Neoplasia, 2007, 9, 662-670.	2.3	89
158	Prostate Specific Membrane Antigen Targeted ¹⁸ F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. Journal of Urology, 2018, 199, 126-132.	0.2	86
159	Modeling Somatic Evolution in Tumorigenesis. PLoS Computational Biology, 2006, 2, e108.	1.5	84
160	Technical challenges in the isolation and analysis of circulating tumor cells. Oncotarget, 2016, 7, 62754-62766.	0.8	84
161	Simulating the Hallmarks of Cancer. Artificial Life, 2006, 12, 617-634.	1.0	83
162	A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). BMC Cancer, 2017, 17, 453.	1.1	83

#	Article	IF	Citations
163	Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. Oncotarget, 2018, 9, 20908-20927.	0.8	82
164	Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples. PLoS ONE, 2016, 11, e0147400.	1.1	82
165	Hematopoietic Stem Cell Niche Is a Potential Therapeutic Target for Bone Metastatic Tumors. Clinical Cancer Research, 2011, 17, 5553-5558.	3.2	81
166	Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls. Seminars in Nuclear Medicine, 2019, 49, 255-270.	2.5	81
167	FYN is overexpressed in human prostate cancer. BJU International, 2009, 103, 171-177.	1.3	79
168	Targeting Chemokine (C-C motif) Ligand 2 (CCL2) as an Example of Translation of Cancer Molecular Biology to the Clinic. Progress in Molecular Biology and Translational Science, 2010, 95, 31-53.	0.9	79
169	Inhibition of Prostate Cancer Bone Metastasis by Synthetic TF Antigen Mimic/Galectin-3 Inhibitor Lactulose-l-Leucine. Neoplasia, 2012, 14, 65-73.	2.3	79
170	Revisiting Seed and Soil: Examining the Primary Tumor and Cancer Cell Foraging in Metastasis. Molecular Cancer Research, 2017, 15, 361-370.	1.5	79
171	PAR1-mediated NFÎºB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. Journal of Cellular Biochemistry, 2005, 96, 641-652.	1.2	78
172	Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer. Nature Reviews Urology, 2017, 14, 90-97.	1.9	78
173	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. Journal of Clinical Oncology, 2019, 37, 923-931.	0.8	78
174	Galectin-3 Is a Nuclear Matrix Protein Which Binds RNA. Biochemical and Biophysical Research Communications, 1995, 217, 292-303.	1.0	77
175	CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. Clinical and Experimental Metastasis, 2008, 25, 765-776.	1.7	76
176	An In Vivo Mouse Model for Human Prostate Cancer Metastasis. Neoplasia, 2008, 10, 371-IN4.	2.3	74
177	Detection of Somatic Copy Number Alterations in Cancer Using Targeted Exome Capture Sequencing. Neoplasia, 2011, 13, 1019-IN21.	2.3	74
178	Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer: Scientific Rationale and Study Design. Clinical Genitourinary Cancer, 2006, 4, 299-302.	0.9	73
179	Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Investigational New Drugs, 2012, 30, 749-757.	1.2	72
180	Ecology meets cancer biology: The cancer swamp promotes the lethal cancer phenotype. Oncotarget, 2015, 6, 9669-9678.	0.8	72

#	Article	IF	Citations
181	Hormone resistance in prostate cancer. Cancer and Metastasis Reviews, 1998, 17, 373-381.	2.7	71
182	An Imaging Biomarker of Early Treatment Response in Prostate Cancer that Has Metastasized to the Bone. Cancer Research, 2007, 67, 3524-3528.	0.4	70
183	Cellular harmonic information transfer through a tissue tensegrity-matrix system. Medical Hypotheses, 1991, 34, 88-95.	0.8	69
184	Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients. Clinical Cancer Research, 2011, 17, 3924-3932.	3.2	69
185	The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Clinical Cancer Research, 2003, 9, 6447-52.	3.2	69
186	Phase II Trial of Copper Depletion with Tetrathiomolybdate as an Antiangiogenesis Strategy in Patients with Hormone-Refractory Prostate Cancer. Oncology, 2006, 71, 168-175.	0.9	68
187	Cyclophosphamide Creates a Receptive Microenvironment for Prostate Cancer Skeletal Metastasis. Cancer Research, 2012, 72, 2522-2532.	0.4	67
188	Systemic Delivery of Oncolytic Adenoviruses Targeting Transforming Growth Factor-Î² Inhibits Established Bone Metastasis in a Prostate Cancer Mouse Model. Human Gene Therapy, 2012, 23, 871-882.	1.4	67
189	RB Loss Promotes Prostate Cancer Metastasis. Cancer Research, 2017, 77, 982-995.	0.4	67
190	Homing of Cancer Cells to the Bone. Cancer Microenvironment, 2011, 4, 221-235.	3.1	66
191	The Effects of Basic Fibroblast Growth Factor and suramin on Cell Motility and Growth of Rat Prostate Cancer Cells. Journal of Urology, 1991, 145, 199-202.	0.2	65
192	GREB1 is a novel androgen-regulated gene required for prostate cancer growth. Prostate, 2006, 66, 886-894.	1.2	65
193	ILâ€4 induces proliferation in prostate cancer PC3 cells under nutrientâ€depletion stress through the activation of the JNKâ€pathway and survivin upâ€regulation. Journal of Cellular Biochemistry, 2012, 113, 1569-1580.	1.2	65
194	Synergy between antiâ€CCL2 and docetaxel as determined by DWâ€MRI in a metastatic bone cancer model. Journal of Cellular Biochemistry, 2009, 107, 58-64.	1.2	64
195	Suppression of Tumor Recurrence and Metastasis by a Combination of the PHSCN Sequence and the Antiangiogenic Compound Tetrathiomolybdate in Prostate Carcinoma. Neoplasia, 2002, 4, 373-379.	2.3	63
196	Phase II Chemoprevention Trial of Oral Fenretinide in Patients at Risk for Adenocarcinoma of the Prostate. American Journal of Clinical Oncology: Cancer Clinical Trials, 1997, 20, 36-39.	0.6	63
197	Bone marrow macrophages support prostate cancer growth in bone. Oncotarget, 2015, 6, 35782-35796.	0.8	62
198	Early castration reduces prostatic carcinogenesis in transgenic mice. Urology, 1999, 54, 1112-1119.	0.5	61

#	Article	IF	Citations
199	Definition of Molecular Determinants of Prostate Cancer Cell Bone Extravasation. Cancer Research, 2013, 73, 942-952.	0.4	61
200	Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, e65-e68.	0.9	61
201	Prospective Evaluation of PSMA-Targeted ¹⁸F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 58-61.	2.8	61
202	Cancer recurrence and lethality are enabled by enhanced survival and reversible cell cycle arrest of polyaneuploid cells. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	61
203	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. European Urology, 2021, 80, 632-640.	0.9	61
204	Cellular interactions in the tropism of prostate cancer to bone. International Journal of Cancer, 2004, 110, 497-503.	2.3	60
205	Inhibition of Decay-Accelerating Factor (CD55) Attenuates Prostate Cancer Growth and Survival In Vivo. Neoplasia, 2006, 8, 69-78.	2.3	60
206	A Phase 3 Trial of 2ÂYears of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. International Journal of Radiation Oncology Biology Physics, 2015, 93, 294-302.	0.4	60
207	Phase III Multi-Institutional Trial of Adjuvant Chemotherapy With Paclitaxel, Estramustine, and Oral Etoposide Combined With Long-Term Androgen Suppression Therapy and Radiotherapy Versus Long-Term Androgen Suppression Plus Radiotherapy Alone for High-Risk Prostate Cancer: Preliminary Toxicity Analysis of RTOG 99-02. International Journal of Radiation Oncology Biology Physics, 2009, 73, 672-678.	0.4	59
208	Role of Transcriptional Corepressor CtBP1 in Prostate Cancer Progression. Neoplasia, 2012, 14, 905-IN8.	2.3	59
209	Disseminated tumor cells and dormancy in prostate cancer metastasis. Current Opinion in Biotechnology, 2016, 40, 9-15.	3.3	59
210	Tenascin-C and Integrin Î±9 Mediate Interactions of Prostate Cancer with the Bone Microenvironment. Cancer Research, 2017, 77, 5977-5988.	0.4	59
211	SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. Journal of Nuclear Medicine, 2018, 59, 1085-1091.	2.8	58
212	Identifying key questions in the ecology and evolution of cancer. Evolutionary Applications, 2021, 14, 877-892.	1.5	58
213	The â€œEmigration, Migration, and Immigrationâ€•of Prostate Cancer. Clinical Prostate Cancer, 2005, 4, 24-30.	2.1	57
214	The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer. Oncotarget, 0, 7, 41217-41232.	0.8	57
215	Computational Modeling of the Crosstalk Between Macrophage Polarization and Tumor Cell Plasticity in the Tumor Microenvironment. Frontiers in Oncology, 2019, 9, 10.	1.3	55
216	Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines. Cancer Letters, 2004, 215, 209-220.	3.2	54

#	Article	IF	Citations
217	Polyâ€aneuploid cancer cells promote evolvability, generating lethal cancer. Evolutionary Applications, 2020, 13, 1626-1634.	1.5	54
218	Detection and Isolation of Circulating Tumor Cells in Urologic Cancers: A Review. Neoplasia, 2004, 6, 302-309.	2.3	53
219	Molecularly Targeted Radiosensitization of Human Prostate Cancer by Modulating Inhibitor of Apoptosis. Clinical Cancer Research, 2008, 14, 7701-7710.	3.2	53
220	A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177â€“labeled Prostate-specific Membrane Antigenâ€“targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. European Urology, 2021, 80, 82-94.	0.9	53
221	In Vivo Evaluation of AT-101 (R-(â€”)-Gossypol Acetic Acid) in Androgen-Independent Growth of VCaP Prostate Cancer Cells in Combination with Surgical Castration. Neoplasia, 2007, 9, 1030-1037.	2.3	52
222	Activation of Urokinase Plasminogen Activator and Its Receptor Axis Is Essential for Macrophage Infiltration in a Prostate Cancer Mouse Model. Neoplasia, 2011, 13, 23-30.	2.3	52
223	Critical transitions in a game theoretic model of tumour metabolism. Interface Focus, 2014, 4, 20140014.	1.5	52
224	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. European Urology Oncology, 2021, 4, 447-455.	2.6	52
225	Skeletal metastasis of prostate adenocarcinoma in rats: Morphometric analysis and role of parathyroid hormone-related protein. , 1999, 39, 187-197.		51
226	Prevalence of Prostate Cancer Metastases after Intravenous Inoculation Provides Clues into the Molecular Basis of Dormancy in the Bone Marrow Microenvironment. Neoplasia, 2012, 14, 429-439.	2.3	51
227	The role of heterogeneous environment and docetaxel gradient in the emergence of polyploid, mesenchymal and resistant prostate cancer cells. Clinical and Experimental Metastasis, 2019, 36, 97-108.	1.7	51
228	O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis. Journal of Clinical Investigation, 2018, 128, 4924-4937.	3.9	51
229	Circulating fibroblastâ€like cells in men with metastatic prostate cancer. Prostate, 2013, 73, 176-181.	1.2	50
230	Magnetic Resonanceâ€“invisible Versus Magnetic Resonanceâ€“visible Prostate Cancer in Active Surveillance: AÂPreliminary Report on Disease Outcomes. Urology, 2015, 85, 147-154.	0.5	50
231	PSMA-Based Detection of Prostate Cancer Bone Lesions With 18F-DCFPyL PET/CT: A Sensitive Alternative to 99mTc-MDP Bone Scan and Na18F PET/CT?. Clinical Genitourinary Cancer, 2016, 14, e115-e118.	0.9	50
232	The prostate cancer bone marrow niche: more than just â€˜fertile soilâ€™. Asian Journal of Andrology, 2012, 14, 423-427.	0.8	50
233	Characterization of the subtypes of cell motility in ageing human skin fibroblasts. Mechanisms of Ageing and Development, 1990, 56, 99-105.	2.2	49
234	LONGITUDINAL COHORT ANALYSIS OF LETHAL PROSTATE CANCER PROGRESSION IN TRANSGENIC MICE. Journal of Urology, 1998, 160, 1500-1505.	0.2	49

#	Article	IF	Citations
235	Expression of the Platelet-Derived Growth Factor Receptor in Prostate Cancer and Treatment Implications with Tyrosine Kinase Inhibitors. Neoplasia, 2004, 6, 503-512.	2.3	49
236	Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Investigational New Drugs, 2011, 29, 1432-1440.	1.2	49
237	Drug Insight: use of docetaxel in prostate and urothelial cancers. Nature Reviews Urology, 2005, 2, 92-100.	1.4	48
238	Convergent Evolution, Evolving Evolvability, and the Origins of Lethal Cancer. Molecular Cancer Research, 2020, 18, 801-810.	1.5	48
239	CCL2, survivin and autophagy: New links with implications in human cancer. Autophagy, 2008, 4, 969-971.	4.3	47
240	Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. European Urology, 2021, 79, 762-771.	0.9	47
241	Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes and Cancer, 2005, 44, 351-364.	1.5	46
242	CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac. Journal of Cellular Biochemistry, 2008, 104, 1587-1597.	1.2	46
243	CCL2 Is a Negative Regulator of AMP-Activated Protein Kinase to Sustain mTOR Complex-1 Activation, Survivin Expression, and Cell Survival in Human Prostate Cancer PC3 Cells. Neoplasia, 2009, 11, 1309-1317.	2.3	46
244	CXCL12Î³ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. Cancer Research, 2018, 78, 2026-2039.	0.4	46
245	Mannose Receptorâ€“positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease. European Urology Oncology, 2019, 2, 429-436.	2.6	46
246	Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer, 1994, 74, 100-103.	2.0	45
247	Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease. Urology, 1999, 54, 319-323.	0.5	45
248	Niche Inheritance: A Cooperative Pathway to Enhance Cancer Cell Fitness Through Ecosystem Engineering. Journal of Cellular Biochemistry, 2014, 115, 1478-1485.	1.2	45
249	Letter to the Editor: Androgens and Prostate Cancer: Are the Descriptors Valid?. Cancer Biology and Therapy, 2005, 4, 4-5.	1.5	44
250	Critical Appraisal of Prostate-specific Antigen in Prostate Cancer Screening: 20 Years Later. Urology, 2009, 73, S11-S20.	0.5	44
251	Disrupting the Networks of Cancer. Clinical Cancer Research, 2012, 18, 2801-2808.	3.2	44
252	Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6457-E6466.	3.3	44

#	Article	IF	Citations
253	Ecological paradigms to understand the dynamics of metastasis. Cancer Letters, 2016, 380, 237-242.	3.2	44
254	A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. Journal of Cellular Biochemistry, 2005, 96, 439-446.	1.2	43
255	Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on ¹⁸F-DCFPyL PET/CT Imaging. Journal of Nuclear Medicine, 2018, 59, 1857-1864.	2.8	43
256	Evidence of porcine and human endothelium activation by cancer-associated carbohydrates expressed on glycoproteins and tumour cells. Journal of Physiology, 2004, 554, 89-99.	1.3	42
257	In vivo real-time imaging of TGF-?-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer. Prostate, 2004, 59, 360-369.	1.2	42
258	Development of the VCaP androgen-independent model of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 161-168.	0.8	42
259	New and Emerging Therapies for Bone Metastases in Genitourinary Cancers. European Urology, 2013, 63, 309-320.	0.9	42
260	Disseminated Prostate Cancer Cells Can Instruct Hematopoietic Stem and Progenitor Cells to Regulate Bone Phenotype. Molecular Cancer Research, 2012, 10, 282-292.	1.5	41
261	Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo. Prostate, 1993, 22, 225-233.	1.2	40
262	Epidemiology of prostate cancer: molecular and environmental clues. Urology, 1996, 48, 676-683.	0.5	40
263	Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. Nature Reviews Urology, 2019, 16, 7-22.	1.9	39
264	Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo. Urology, 1996, 48, 164-170.	0.5	38
265	Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology, 2005, 65, 616-621.	0.5	38
266	Inhibitory effects of megakaryocytic cells in prostate cancer skeletal metastasis. Journal of Bone and Mineral Research, 2011, 26, 125-134.	3.1	38
267	Semiquantitative Parameters in PSMA-Targeted PET Imaging with ¹⁸F-DCFPyL: Variability in Normal-Organ Uptake. Journal of Nuclear Medicine, 2017, 58, 942-946.	2.8	38
268	Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. Urology, 2005, 66, 658.e1-658.e3.	0.5	37
269	â^'(â^')Gossypol promotes the apoptosis of bladder cancer cells in vitro. Pharmacological Research, 2008, 58, 323-331.	3.1	37
270	Genetic Ablation of Metadherin Inhibits Autochthonous Prostate Cancer Progression and Metastasis. Cancer Research, 2014, 74, 5336-5347.	0.4	37

#	Article	IF	Citations
271	Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications. Annals of Nuclear Medicine, 2018, 32, 512-522.	1.2	37
272	Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. International Journal of Radiation Oncology Biology Physics, 2019, 105, 948-956.	0.4	37
273	AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer. Molecular Cancer Research, 2019, 17, 356-369.	1.5	36
274	Wnt Signaling Drives Prostate Cancer Bone Metastatic Tropism and Invasion. Translational Oncology, 2020, 13, 100747.	1.7	36
275	ROS-induced cell cycle arrest as a mechanism of resistance in polyaneuploid cancer cells (PACCs). Progress in Biophysics and Molecular Biology, 2021, 165, 3-7.	1.4	36
276	Nanoparticle Induced Cell Magneto-Rotation: Monitoring Morphology, Stress and Drug Sensitivity of a Suspended Single Cancer Cell. PLoS ONE, 2011, 6, e28475.	1.1	36
277	Phenotypic characterization of immortalized normal and primary tumor-derived human prostate epithelial cell cultures. Prostate, 2000, 44, 164-171.	1.2	35
278	Expression of Nuclear Antigen Ki-67 in Prostate Cancer Needle Biopsy and Radical Prostatectomy Specimens. Journal of the National Cancer Institute, 2000, 92, 1941-1942.	3.0	35
279	Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer, 2003, 98, 1603-1610.	2.0	35
280	Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology, 2003, 62, 128-133.	0.5	35
281	The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion. Molecular Oncology, 2017, 11, 655-669.	2.1	35
282	Meeting report from the Prostate Cancer Foundation PSMAâ€directed radionuclide scientific working group. Prostate, 2018, 78, 775-789.	1.2	35
283	CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies. Clinical Cancer Research, 2020, 26, 1953-1964.	3.2	35
284	Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. Cancer, 2003, 98, 269-276.	2.0	34
285	Analysis of membrane-bound complement regulatory proteins in prostate cancer. Urology, 2005, 66, 1321-1326.	0.5	34
286	Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL in peripheral ganglia. Annals of Nuclear Medicine, 2017, 31, 696-702.	1.2	34
287	PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells. Journal of Cellular Biochemistry, 2007, 101, 1292-1300.	1.2	33
288	Frequent discordance betweenERGgene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. Prostate, 2014, 74, 1199-1208.	1.2	33

#	Article	IF	Citations
289	A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines. Cancer Letters, 1993, 70, 159-166.	3.2	32
290	Loss of cell-contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells. International Journal of Cancer, 1995, 63, 100-105.	2.3	32
291	Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study. Prostate, 2000, 44, 275-278.	1.2	32
292	Novel surface expression of reticulocalbin 1 on bone endothelial cells and human prostate cancer cells is regulated by TNFâ€Î±. Journal of Cellular Biochemistry, 2008, 104, 2298-2309.	1.2	31
293	A sequence-based survey of the complex structural organization of tumor genomes. Genome Biology, 2008, 9, R59.	13.9	31
294	TAM macrophages promote growth and metastasis within the cancer ecosystem. OncoImmunology, 2014, 3, e941734.	2.1	30
295	Oligometastatic prostate cancer. Current Opinion in Urology, 2017, 27, 533-541.	0.9	30
296	Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer. Cancer Research, 2021, 81, 5948-5962.	0.4	30
297	A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407). Prostate, 2001, 46, 257-261.	1.2	29
298	The regulation of prostate cancer cell adhesion to human bone marrow endothelial cell monolayers by androgen dihydrotestosterone and cytokines. Clinical and Experimental Metastasis, 2002, 19, 25-33.	1.7	29
299	Risk prediction tool for grade reâ€classification in men with favourableâ€risk prostate cancer on active surveillance. BJU International, 2017, 120, 25-31.	1.3	29
300	Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories. Journal of Nuclear Medicine, 2019, 60, 511-516.	2.8	29
301	Modeling invasion of metastasizing cancer cells to bone marrow utilizing ecological principles. Theoretical Biology and Medical Modelling, 2011, 8, 36.	2.1	28
302	Endothelial integrin Î±3Î²1 stabilizes carbohydrate-mediated tumor/endothelial cell adhesion and induces macromolecular signaling complex formation at the endothelial cell membrane. Oncotarget, 2014, 5, 1382-1389.	0.8	28
303	Dynamic Regulation of Rad51 by E2F1 and p53 in Prostate Cancer Cells upon Drug-Induced DNA Damage under Hypoxia. Molecular Pharmacology, 2014, 85, 866-876.	1.0	28
304	Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer. European Urology Oncology, 2021, 4, 310-314.	2.6	28
305	In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biology and Therapy, 2003, 2, 656-60.	1.5	28
306	Continuous real time ex vivo epifluorescent video microscopy for the study of metastatic cancer cell interactions with microvascular endothelium. Clinical and Experimental Metastasis, 2003, 20, 451-458.	1.7	27

#	Article	IF	Citations
307	Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts. Journal of Cellular Biochemistry, 2009, 106, 563-569.	1.2	27
308	Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging. Journal of Nuclear Medicine, 2018, 59, 486-493.	2.8	27
309	Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake. Molecular Imaging and Biology, 2020, 22, 190-197.	1.3	27
310	Prospective Comparison of PET Imaging with PSMA-Targeted ¹⁸F-DCFPyL Versus Na¹⁸F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 183-188.	2.8	27
311	Interplay between Cell Death and Cell Proliferation Reveals New Strategies for Cancer Therapy. International Journal of Molecular Sciences, 2022, 23, 4723.	1.8	27
312	Inhibition of prostate cancer growth by estramustine and colchicine. Prostate, 1995, 26, 310-315.	1.2	26
313	Genetic Characterization of Immortalized Human Prostate Epithelial Cell Cultures. Cancer Genetics and Cytogenetics, 2000, 120, 50-57.	1.0	26
314	Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration. BMC Cancer, 2017, 17, 447.	1.1	26
315	The effect of extracellular matrix interactions on morphologic transformation invitro. Biochemical and Biophysical Research Communications, 1991, 179, 333-339.	1.0	25
316	Prostate Cancer and Parasitism of the Bone Hematopoietic Stem Cell Niche. Critical Reviews in Eukaryotic Gene Expression, 2012, 22, 131-148.	0.4	25
317	Prostate cancer research: The next generation; report from the 2019 Coffeyâ€Holden Prostate Cancer Academy Meeting. Prostate, 2020, 80, 113-132.	1.2	25
318	Uptake of Prostate-Specific Membrane Antigenâ€“Targeted 18F-DCFPyL in Cerebral Radionecrosis. Clinical Nuclear Medicine, 2018, 43, e419-e421.	0.7	24
319	Novel Structured Reporting Systems for Theranostic Radiotracers. Journal of Nuclear Medicine, 2019, 60, 577-584.	2.8	24
320	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigenâ€“Targeted ¹⁸F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. Journal of Nuclear Medicine, 2021, 62, 1430-1437.	2.8	24
321	Tumor Repression of VCaP Xenografts by a Pyrrole-Imidazole Polyamide. PLoS ONE, 2015, 10, e0143161.	1.1	24
322	Modifications of the intermediate filament and nuclear matrix networks by the extracellular matrix. Biochemical and Biophysical Research Communications, 1991, 179, 340-344.	1.0	23
323	Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility. Prostate, 1992, 20, 233-241.	1.2	23
324	A Bayesian Hierarchical Model for Prediction of Latent Health States from Multiple Data Sources with Application to Active Surveillance of Prostate Cancer. Biometrics, 2017, 73, 625-634.	0.8	23

#	Article	IF	Citations
325	Primary Outcomes of a Phase II Randomized Trial of Observation Versus Stereotactic Ablative Radiation for OLigometastatic Prostate CancEr (ORIOLE). International Journal of Radiation Oncology Biology Physics, 2019, 105, 681.	0.4	23
326	Extracellular vesicle isolation from human renal cancer tissue. Medical Oncology, 2020, 37, 28.	1.2	23
327	3D Shape Modeling for Cell Nuclear Morphological Analysis and Classification. Scientific Reports, 2018, 8, 13658.	1.6	22
328	Effects of extracellular matrix components and dihydrotestosterone on the structure and function of human prostate cancer cells. Prostate, 1992, 20, 29-41.	1.2	21
329	An unstable nuclear matrix may contribute to genetic instability. Medical Hypotheses, 1994, 42, 45-52.	0.8	21
330	Expression mapping at 12p12-13 in advanced prostate carcinoma. International Journal of Cancer, 2004, 109, 668-672.	2.3	21
331	ATâ€101 (Râ€(â^')â€gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model. Journal of Cellular Biochemistry, 2010, 110, 1187-1194.	1.2	21
332	Alternative CD44 splicing identifies epithelial prostate cancer cells from the mesenchymal counterparts. Medical Oncology, 2015, 32, 159.	1.2	21
333	Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. Journal of Urology, 2018, 199, 1494-1501.	0.2	21
334	Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. World Journal of Urology, 2019, 37, 2623-2629.	1.2	21
335	CD38 in Advanced Prostate Cancers. European Urology, 2021, 79, 736-746.	0.9	21
336	Symmetry and symmetry breaking in cancer: a foundational approach to the cancer problem. Oncotarget, 2018, 9, 11429-11440.	0.8	21
337	Successfully Accelerating Translational Research at an Academic Medical Center: The University of Michigan-Coulter Translational Research Partnership Program. Clinical and Translational Science, 2010, 3, 316-318.	1.5	20
338	Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer. European Urology, 2017, 72, 135-141.	0.9	20
339	¹⁷⁷Luâ€PSMA radioligand therapy effectiveness in metastatic castrationâ€resistant prostate cancer: An updated systematic review and metaâ€analysis. Prostate, 2022, 82, 826-835.	1.2	20
340	A common set of nuclear matrix proteins in prostate cancer cells. Prostate, 1993, 23, 61-67.	1.2	19
341	Coupling of cell structure to cell metabolism and function. Journal of Cellular Biochemistry, 1994, 55, 16-21.	1.2	19
342	A new concept in cancer care: The supportive care program. American Journal of Hospice and Palliative Medicine, 1999, 16, 713-722.	0.8	19

#	Article	IF	Citations
343	Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort. Clinical Cancer Research, 2011, 17, 1546-1552.	3.2	19
344	Analogous detection of circulating tumor cells using the AccuCyte^{Â®}â€"CyteFinder^{Â®} system and ISET system in patients with locally advanced and metastatic prostate cancer. Prostate, 2018, 78, 300-307.	1.2	19
345	Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 387-395.	0.4	19
346	Characterization of nuclear morphology and nuclear matrices in ageing human fibroblasts. Mechanisms of Ageing and Development, 1992, 62, 13-24.	2.2	18
347	Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer. Prostate, 2019, 79, 1715-1727.	1.2	18
348	Radiation Therapy Oncology Group 0521: A Phase III Randomized Trial of Androgen Suppression and Radiation Therapy Versus Androgen Suppression and Radiation Therapy Followed by Docetaxel/Prednisone for Localized, High-Risk Prostate Cancer. Clinical Genitourinary Cancer, 2005, 4, 212-214.	0.9	17
349	Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting. Prostate, 2016, 76, 125-139.	1.2	17
350	Integrin alpha V beta 3 targeted dendrimerâ€rapamycin conjugate reduces fibroblastâ€mediated prostate tumor progression and metastasis. Journal of Cellular Biochemistry, 2018, 119, 8074-8083.	1.2	17
351	Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. Prostate Cancer and Prostatic Diseases, 2022, 25, 713-719.	2.0	17
352	Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone. Bone, 2011, 48, 1354-1361.	1.4	16
353	Epithelial-mesenchymal transition in prostate cancer is associated with quantifiable changes in nuclear structure. Prostate, 2015, 75, 218-224.	1.2	16
354	Biomanufacturing Seamless Tubular and Hollow Collagen Scaffolds with Unique Design Features and Biomechanical Properties. Advanced Healthcare Materials, 2017, 6, 1601136.	3.9	16
355	Cell surface Thomsen-Friedenreich proteome profiling of metastatic prostate cancer cells reveals potential link with cancer stem cell-like phenotype. Oncotarget, 2017, 8, 98598-98608.	0.8	16
356	A Voice From the Past: Rediscovering the Virchow Node With Prostate-specific Membrane Antigen-targeted 18 F-DCFPyL Positron Emission Tomography Imaging. Urology, 2018, 117, 18-21.	0.5	16
357	Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method. Urology, 2018, 115, 82-86.	0.5	16
358	Recent advances in extracellular vesicle research for urological cancers: From technology to application. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 342-360.	3.3	16
359	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate, 2020, 80, 1273-1296.	1.2	16
360	A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). BMC Cancer, 2020, 20, 492.	1.1	16

#	Article	IF	Citations
361	Cancer Cells and M2 Macrophages: Cooperative Invasive Ecosystem Engineers. Cancer Control, 2020, 27, 107327482091105.	0.7	16
362	AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort.. Journal of Clinical Oncology, 2016, 34, 5012-5012.	0.8	16
363	Cancer Foraging Ecology: Diet Choice, Patch Use, and Habitat Selection of Cancer Cells. Current Pathobiology Reports, 2018, 6, 209-218.	1.6	15
364	High-Throughput Simultaneous mRNA Profiling Using nCounter Technology Demonstrates That Extracellular Vesicles Contain Different mRNA Transcripts Than Their Parental Prostate Cancer Cells. Analytical Chemistry, 2021, 93, 3717-3725.	3.2	15
365	Cancer Cells Homing to Bone: The Significance of Chemotaxis and Cell Adhesion. Cancer Treatment and Research, 2004, 118, 291-309.	0.2	15
366	A method to measure cellular adhesion utilizing a polymer micro-cantilever. Applied Physics Letters, 2013, 103, 123702.	1.5	14
367	Beyond the androgen receptor: New approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting. Prostate, 2014, 74, 314-320.	1.2	14
368	A multi-targeted approach to treating bone metastases. Cancer and Metastasis Reviews, 2014, 33, 545-553.	2.7	14
369	Drug discovery in prostate cancer mouse models. Expert Opinion on Drug Discovery, 2015, 10, 1011-1024.	2.5	14
370	The Presence of Androgen Receptor Elements Regulates ZEB1 Expression in the Absence of Androgen Receptor. Journal of Cellular Biochemistry, 2015, 116, 115-123.	1.2	14
371	Nucleolin Staining May Aid in the Identification of Circulating Prostate Cancer Cells. Clinical Genitourinary Cancer, 2017, 15, e477-e481.	0.9	14
372	The Identification of Macrophage-enriched Glycoproteins Using Glycoproteomics. Molecular and Cellular Proteomics, 2017, 16, 1029-1037.	2.5	14
373	3D Cell Nuclear Morphology: Microscopy Imaging Dataset and Voxel-Based Morphometry Classification Results. , 2018, , .		14
374	Optimization of Immunofluorescent Detection of Bone Marrow Disseminated Tumor Cells. Biological Procedures Online, 2018, 20, 13.	1.4	14
375	Optimization of prostate cancer cell detection using multiplex tyramide signal amplification. Journal of Cellular Biochemistry, 2019, 120, 4804-4812.	1.2	14
376	Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake. Molecular Imaging and Biology, 2020, 22, 181-189.	1.3	14
377	High KIFC1 expression is associated with poor prognosis in prostate cancer. Medical Oncology, 2021, 38, 47.	1.2	14
378	The effect of age on the response of the detrusor to intracellular mechanical stimulus: DNA replication and the cell actin matrix. Journal of Cellular Biochemistry, 1992, 48, 373-384.	1.2	13

#	Article	IF	Citations
379	Inhibition of prostate cancer growth by vinblastine and tamoxifen. Prostate, 1995, 26, 270-274.	1.2	13
380	Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line. Urology, 1999, 54, 746-752.	0.5	13
381	Etoposide in prostate cancer. Expert Opinion on Pharmacotherapy, 2000, 1, 271-275.	0.9	13
382	Role of dutasteride in preâ€clinical ETS fusionâ€positive prostate cancer models. Prostate, 2012, 72, 1542-1549.	1.2	13
383	A bioinformatics approach reveals novel interactions of the OVOL transcription factors in the regulation of epithelial â€“ mesenchymal cell reprogramming and cancer progression. BMC Systems Biology, 2014, 8, 29.	3.0	13
384	Murine Prostate Micro-dissection and Surgical Castration. Journal of Visualized Experiments, 2016, , .	0.2	13
385	PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis. Prostate, 2018, 78, 547-559.	1.2	13
386	Absence of myeloid Klf4 reduces prostate cancer growth with pro-atherosclerotic activation of tumor myeloid cells and infiltration of CD8 T cells. PLoS ONE, 2018, 13, e0191188.	1.1	13
387	Tumor cell heterogeneity and resistance; report from the 2018 Coffeyâ€Holden Prostate Cancer Academy Meeting. Prostate, 2019, 79, 244-258.	1.2	13
388	Online Prostate-Specific Membrane Antigen and Positron Emission Tomographyâ€“Guided Radiation Therapy for Oligometastatic Prostate Cancer. Advances in Radiation Oncology, 2020, 5, 260-268.	0.6	13
389	The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Journal of Nuclear Medicine, 2022, 63, 248-252.	2.8	13
390	Possible mechanism of CCL2-induced Akt activation in prostate cancer cells. Anticancer Research, 2009, 29, 3109-13.	0.5	13
391	Discussion. Urology, 1999, 53, 1073-1076.	0.5	12
392	The truth is out there: an overall perspective on androgen deprivation. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 272-281.	0.8	12
393	Beyond immune checkpoint blockade: New approaches to targeting host-tumor interactions in prostate cancer: Report from the 2014 Coffey-Holden prostate cancer Academy meeting. Prostate, 2015, 75, 337-347.	1.2	12
394	Epithelial and mesenchymal prostate cancer cell population dynamics on a complex drug landscape. Convergent Science Physical Oncology, 2017, 3, 045001.	2.6	12
395	Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18 F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer. Journal of Urology, 2020, 204, 496-502.	0.2	12
396	Predictors of ¹⁸F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy. Journal of Nuclear Medicine, 2022, 63, 1184-1190.	2.8	12

#	Article	IF	Citations
397	THE USE OF PROSTATE-SPECIFIC ANTIGEN AS A SURROGATE END POINT IN THE TREATMENT OF PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER. Urologic Clinics of North America, 1997, 24, 433-437.	0.8	11
398	Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis. Journal of Cellular Biochemistry, 2013, 114, 2471-2478.	1.2	11
399	Cancer as a Social Dysfunctionâ€"Why Cancer Research Needs New Thinking. Molecular Cancer Research, 2018, 16, 1346-1347.	1.5	11
400	Lipid droplet evolution gives insight into polyaneuploid cancer cell lipid droplet functions. Medical Oncology, 2021, 38, 133.	1.2	11
401	Proptosis and decreased vision secondary to prostate cancer orbital wall metastasis. Anticancer Research, 2005, 25, 3521-2.	0.5	11
402	Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma. Cancer, 2006, 106, 1715-1721.	2.0	10
403	Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer. Molecular Imaging and Biology, 2019, 21, 1054-1063.	1.3	10
404	Characterization of tumorâ€associated macrophages in prostate cancer transgenic mouse models. Prostate, 2021, 81, 629-647.	1.2	10
405	A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT.. Journal of Clinical Oncology, 2020, 38, 9-9.	0.8	10
406	Characterization of Cellular and Acellular Analytes from Pre-Cystectomy Liquid Biopsies in Patients Newly Diagnosed with Primary Bladder Cancer. Cancers, 2022, 14, 758.	1.7	10
407	Robots as models of evolving systems. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2120019119.	3.3	10
408	Testicular cancer. Current Opinion in Oncology, 2004, 16, 253-256.	1.1	9
409	Integrated Multimodal Imaging of Dynamic Bone-Tumor Alterations Associated with Metastatic Prostate Cancer. PLoS ONE, 2015, 10, e0123877.	1.1	9
410	Aerobic glycolysis, motility, and cytoskeletal remodeling. Cell Cycle, 2015, 14, 169-170.	1.3	9
411	CTâ€based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castrationâ€resÃ¯ve oligometastatic prostate cancer. Prostate, 2021, 81, 127-134.	1.2	9
412	The role of liquid biopsies in prostate cancer management. Lab on A Chip, 2021, 21, 3263-3288.	3.1	9
413	Piflufolastat F-18 (¹⁸F-DCFPyL) for PSMA PET imaging in prostate cancerâ€¯. Expert Review of Anticancer Therapy, 2022, 22, 681-694.	1.1	9
414	Inhibition of prostate cancer growth by estramustine and etoposide. Cancer, 1995, 75, 1920-1926.	2.0	8

#	Article	IF	Citations
415	Evidence for lectin signaling to the nuclear matrix: Cellular interpretation of the glycocode. Journal of Cellular Biochemistry, 2000, 79, 123-129.	1.2	8
416	Mind-body effect: insulinlike growth factor-1; clinical depression; and breast, prostate, and other cancer riskâ€"an unmeasured and masked mediator of potential significance?. Urology, 2002, 59, 4-8.	0.5	8
417	Phase II Evaluation of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Patients with Hormone-Sensitive Prostate Adenocarcinoma. Clinical Genitourinary Cancer, 2007, 5, 318-322.	0.9	8
418	Prostate Cancer Local Recurrence Detected With Both 18 F-Fluciclovine and PSMA-targeted 18 F-DCFPyL PET/CT. Urology, 2017, 107, e9-e10.	0.5	8
419	Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. Radiotherapy and Oncology, 2019, 141, 137-143.	0.3	8
420	Cancer cell foraging to explain bone-specific metastatic progression. Bone, 2022, 158, 115788.	1.4	8
421	An in vitro tumor swamp model of heterogeneous cellular and chemotherapeutic landscapes. Lab on A Chip, 2020, 20, 2453-2464.	3.1	8
422	Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine. Urology, 1996, 48, 508-511.	0.5	7
423	Effect of organ site on nuclear matrix protein composition. , 1996, 62, 132-141.		7
424	Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma. Cancer, 2001, 91, 2175-2180.	2.0	7
425	Antimetastatic Drugs in Prostate Cancer. Clinical Prostate Cancer, 2002, 1, 14-19.	2.1	7
426	Germ cell tumors: review of selected studies from 2002. Current Opinion in Oncology, 2003, 15, 234-238.	1.1	7
427	Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffeyâ€Holden Prostate Cancer Academy Meeting. Prostate, 2017, 77, 1478-1488.	1.2	7
428	Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18 F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation. Urology Case Reports, 2018, 17, 22-25.	0.1	7
429	The combination of sizeâ€based separation and selectionâ€free technology provides higher circulating tumour cells detection sensitivity than either method alone in patients with metastatic prostate cancer. BJU International, 2020, 126, 191-201.	1.3	7
430	NF-Îºß p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma. , 2020, 8, e000244.		7
431	A Phase II Evaluation of Oral Tamoxifen and Intermittent Intravenous Vinblastine in Hormone-Refractory Adenocarcinoma of the Prostate. American Journal of Clinical Oncology: Cancer Clinical Trials, 1996, 19, 500-503.	0.6	7
432	Advancements in the identification of EV derived mRNA biomarkers for liquid biopsy of clear cell renal cell carcinomas. Urology, 2022, 160, 87-93.	0.5	7

#	Article	IF	Citations
433	The Tissue Matrix and The Regulation of Gene Expression in Cancer Cells. Advances in Molecular and Cell Biology, 1993, 7, 131-156.	0.1	6
434	ORAL CHEMOTHERAPY FOR HORMONE REFRACTORY PROSTATE CANCER. Urologic Clinics of North America, 1999, 26, 333-340.	0.8	6
435	Testicular cancer. Current Opinion in Oncology, 2002, 14, 260-264.	1.1	6
436	Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy. Urology, 2003, 62, 95-101.	0.5	6
437	Tomlins et al. reply. Nature, 2009, 457, E2-E3.	13.7	6
438	Re: Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-resistant Prostate Cancer Cell Lines. European Urology, 2013, 64, 339-340.	0.9	6
439	Role of biobanking in urology: a review. BJU International, 2016, 118, 864-868.	1.3	6
440	A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy. Advances in Radiation Oncology, 2016, 1, 59-66.	0.6	6
441	Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffeyâ€“Holden Prostate Cancer Academy Meeting. Prostate, 2017, 77, 123-144.	1.2	6
442	Cancer dormancy and criticality from a game theory perspective. Cancer Convergence, 2018, 2, 1.	8.0	6
443	Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications?. Translational Andrology and Urology, 2019, 8, S263-S264.	0.6	6
444	Detection of Early Progression with ¹⁸F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. Journal of Nuclear Medicine, 2021, 62, 1270-1273.	2.8	6
445	Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer. Diagnostics, 2021, 11, 665.	1.3	6
446	Polyaneuploid Cancer Cell Dormancy: Lessons From Evolutionary Phyla. Frontiers in Ecology and Evolution, 2021, 9, .	1.1	6
447	High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with ¹⁸F-DCFPyL. Molecular Imaging, 2022, 2022, 7056983.	0.7	6
448	Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. Medical Oncology, 2022, 39, 63.	1.2	6
449	Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer. Oncogene, 2022, 41, 3747-3760.	2.6	6
450	Modified Differential Display Technique that Eliminates Radioactivity and Decreases Screening Time. BioTechniques, 2000, 28, 272-277.	0.8	5

#	Article	IF	Citations
451	Quantitative Analysis of Circulating Tumor Cells as a Survival Predictor in Metastatic Castrationâ€“Resistant Prostate Cancer: Missing Parts in a Superb Study. Clinical Cancer Research, 2009, 15, 1504-1505.	3.2	5
452	The CTSA Mandate: Are We There Yet?. Research and Theory for Nursing Practice, 2010, 24, 64-73.	0.2	5
453	A surface tension magnetophoretic device for rare cell isolation and characterization. Medical Oncology, 2017, 34, 22.	1.2	5
454	Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi. Nuclear Medicine Communications, 2017, 38, 795-798.	0.5	5
455	PSMA-targeted [18F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework. Urology Case Reports, 2019, 23, 72-74.	0.1	5
456	Prospective evaluation of 68Ga-PSMA-11 PET/CT in Chinese men with biochemical recurrence after radical prostatectomy for prostate cancer: relationships between location of recurrence, time after prostatectomy, and serum PSA level. Medical Oncology, 2020, 37, 89.	1.2	5
457	The issues with tissues: the wide range of cell fate separation enables the evolution of multicellularity and cancer. Medical Oncology, 2020, 37, 62.	1.2	5
458	Understanding the tumor-immune microenvironment in prostate cancer. Current Opinion in Oncology, 2021, 33, 231-237.	1.1	5
459	Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro. Medical Oncology, 2021, 38, 105.	1.2	5
460	A simple selection-free method for detecting disseminated tumor cells (DTCs) in murine bone marrow. Oncotarget, 2016, 7, 69794-69803.	0.8	5
461	Cell-morphodynamic phenotype classification with application to cancer metastasis using cell magnetorotation and machine-learning. PLoS ONE, 2021, 16, e0259462.	1.1	5
462	Explaining Aberrations of Cell Structure and Cell Signaling in Cancer Using Complex Adaptive Systems. Advances in Molecular and Cell Biology, 1997, 24, 207-247.	0.1	4
463	Oral Chemotherapy in the Treatment of Hormone-Refractory Prostate Cancer. Drugs, 1999, 58, 127-131.	4.9	4
464	Recent advances in chemotherapy for advanced prostate cancer. Current Urology Reports, 2000, 1, 48-56.	1.0	4
465	Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. Cancer, 2006, 106, 2617-2623.	2.0	4
466	Chemical transfection of dye-conjugated microRNA precursors for microRNA functional analysis of M2 macrophages. Journal of Cellular Biochemistry, 2011, 113, n/a-n/a.	1.2	4
467	Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT. Urology Case Reports, 2018, 16, 86-88.	0.1	4
468	Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assaysâ€”Reply. JAMA Oncology, 2018, 4, 1431.	3.4	4

#	Article	IF	Citations
469	Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types. International Journal of Molecular Sciences, 2020, 21, 9031.	1.8	4
470	A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY).. Journal of Clinical Oncology, 2018, 36, TPS5092-TPS5092.	0.8	4
471	Hormonal and Chemotherapeutic Systemic Therapy for Metastatic Prostate Cancer. Cancer Control, 1996, 3, 493-500.	0.7	3
472	The Clinical and Translational Science Awards (CTSAs) Are Transforming the Way Academic Medical Institutions Approach Translational Research: The University of Michigan Experience. Clinical and Translational Science, 2011, 4, 233-235.	1.5	3
473	Positive Feedback Loops Between Inflammatory, Bone and Cancer Cells During Metastatic Niche Construction. Advances in Experimental Medicine and Biology, 2016, 936, 137-148.	0.8	3
474	Defining the clinical utility of PSMAâ€targeted PET imaging of prostate cancer. BJU International, 2017, 120, 160-161.	1.3	3
475	Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT. Clinical Nuclear Medicine, 2019, 44, e313-e314.	0.7	3
476	Game Theory Cancer Models of Cancer Cell-Stromal Cell Dynamics using Interacting Particle Systems. Biophysical Reviews and Letters, 2020, 15, 171-193.	0.9	3
477	A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization. Prostate Cancer and Prostatic Diseases, 2021, 24, 220-232.	2.0	3
478	Results of a phase II trial of neoadjuvant abiraterone + prednisone+ enzalutamide + leuprolide (APEL) versus enzalutamide + leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP).. Journal of Clinical Oncology, 2018, 36, 79-79.	0.8	3
479	Diagnostic performance of ¹⁸F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of ¹⁸F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC).. Journal of Clinical Oncology, 2019, 37, 5012-5012.	0.8	3
480	Uptake of prostate-specific membrane antigen-targeted 18F-DCFPyL in avascular necrosis of the femoral head. World Journal of Nuclear Medicine, 2019, 18, 416-419.	0.3	3
481	It doesnâ€™t always pay to be fit: success landscapes. Journal of Biological Physics, 2021, 47, 387-400.	0.7	3
482	Measurement of PET Quantitative Bias In Vivo. Journal of Nuclear Medicine, 2021, 62, 732-737.	2.8	3
483	Targeting B7-H3 in prostate cancer: Phase 2 trial in localized prostate cancer using the anti-B7-H3 antibody enoblituzumab, with biomarker correlatives.. Journal of Clinical Oncology, 2022, 40, 5015-5015.	0.8	3
484	Electroretinographic findings in subjects after administration of fenretinide. Documenta Ophthalmologica, 1995, 91, 299-309.	1.0	2
485	Oligometastatic Prostate Cancer to the Navicular Bone: Case Report. Urology Case Reports, 2015, 3, 59-62.	0.1	2
486	Selectionâ€free method reveals phenotypic diversity among prostate cancer circulating tumour cells. BJU International, 2017, 120, E4.	1.3	2

#	Article	IF	Citations
487	Interim Results of a Randomized Trial of Observation Versus SABR for Castration-Sensitive Oligometastatic Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, e134-e135.	0.4	2
488	Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation. Journal of Visualized Experiments, 2019, , .	0.2	2
489	A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.. Journal of Clinical Oncology, 2021, 39, 32-32.	0.8	2
490	Peripheral androgen blockade in men with castrate-sensitive biochemical recurrent prostate cancer. Medical Oncology, 2021, 38, 80.	1.2	2
491	Reply by Authors. Journal of Urology, 2021, 206, 61-61.	0.2	2
492	Androgen-independent Prostate Cancer: The Evolving Role of Chemotherapy. , 2003, , 423-433.		2
493	Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer.. Journal of Clinical Oncology, 2017, 35, 5020-5020.	0.8	2
494	Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted 18F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern. World Journal of Nuclear Medicine, 2019, 18, 424-427.	0.3	2
495	Prostate cancer research in the 21st century; report from the 2021 Coffeyâ€Holden prostate cancer academy meeting. Prostate, 2021, , .	1.2	2
496	Ten unanswered questions in cancer: "If this is true, what does it imply"?. American Journal of Clinical and Experimental Urology, 2018, 6, 26-31.	0.4	2
497	Prostate cancer presenting as visual changes. Anticancer Research, 2006, 26, 755-8.	0.5	2
498	Prostate-specific membrane antigen PET response associates with radiographic progression-free survival following stereotactic ablative radiation therapy in oligometastatic castration-sensitive prostate cancer.. Journal of Clinical Oncology, 2022, 40, 5011-5011.	0.8	2
499	Alterations in cellular gene expression without changes in nuclear matrix protein content. Journal of Cellular Biochemistry, 1994, 56, 502-509.	1.2	1
500	Re: RANKL Inhibition Is an Effective Adjuvant for Docetaxel in a Prostate Cancer Bone Metastasis Model. European Urology, 2008, 54, 688.	0.9	1
501	Forging the Association for Clinical and Translational Science (ACTS). Clinical and Translational Science, 2012, 5, 117-118.	1.5	1
502	Response to â€œComment on â€˜A method to measure cellular adhesion utilizing a polymer micro-cantileverâ€™â€•[Appl. Phys. Lett. 104, 236103 (2014)]. Applied Physics Letters, 2014, 104, 236104.	1.5	1
503	A multi-targeted approach to treating bone metastases. , 2015, , 647-655.		1
504	An Unusual Case of Penile Prostate Cancer Uncovered by Multiparametric MRI and PSMA-Targeted 18F-DCFPyL PET/CT. Clinical Nuclear Medicine, 2017, 42, e441-e443.	0.7	1

#	Article	IF	Citations
505	Re: Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. European Urology, 2018, 73, 478.	0.9	1
506	SABR Produces Systemic Adaptive Immune Responses in Castration-Sensitive Oligometastatic Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2018, 102, S24-S25.	0.4	1
507	Skeletal metastasis of prostate adenocarcinoma in rats: Morphometric analysis and role of parathyroid hormoneâ€related protein. Prostate, 1999, 39, 187-197.	1.2	1
508	Role of the nuclear matrix in breast cancer. Cancer Treatment and Research, 1996, 83, 127-140.	0.2	1
509	PD38-05â€ƒCLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED ¹⁸ F-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIAL. Journal of Urology, 2020, 203, .	0.2	1
510	Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer. Asian Journal of Andrology, 2015, 17, 936.	0.8	1
511	Abstract 4582: Mannose receptor positive macrophage infiltrate correlates with prostate cancer onset and metastatic castration-resistant disease. , 2019, , .		1
512	A phase II randomized trial of RAdium-223 dichloride and SABR versus SABR for oligomEtastatic prostate caNcerS (RAVENS).. Journal of Clinical Oncology, 2020, 38, TPS5586-TPS5586.	0.8	1
513	A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).. Journal of Clinical Oncology, 2020, 38, 116-116.	0.8	1
514	Immune profiling of the bone marrow microenvironment in patients with high-risk localized prostate cancer. Oncotarget, 2020, 11, 4253-4265.	0.8	1
515	Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score.. Journal of Clinical Oncology, 2022, 40, 5024-5024.	0.8	1
516	RATIONAL USE OF CHEMOTHERAPY. Urologic Clinics of North America, 1999, 26, 275-279.	0.8	0
517	Current Chemotherapy Regimens. Urologic Clinics of North America, 1999, 26, 419-421.	0.8	0
518	Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone. , 2002, , 197-213.		0
519	Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 73-74.	0.8	0
520	Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA). Urologic Oncology: Seminars and Original Investigations, 2005, 23, 74.	0.8	0
521	Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 75.	0.8	0
522	Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 75.	0.8	0

#	Article	IF	Citations
523	Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 76.	0.8	0
524	Bone metastasis and cancer. Cancer and Metastasis Reviews, 2007, 25, 505-505.	2.7	0
525	Prostate Cancer Metastasis: Thoughts on Biology and Therapeutics. , 0, , 456-464.		0
526	Molecular Mechanisms of Prostate Cancer Progression After Castration. Current Clinical Urology, 2014, , 31-41.	0.0	0
527	A Novel Approach for Performing Bone Marrow Aspiration at the Time of Radical Prostatectomy. Urology Case Reports, 2016, 6, 45-46.	0.1	0
528	Clinical Outcomes in Oligometastatic Prostate Cancer Following Definitive Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 105, E573-E574.	0.4	0
529	Re: Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy of Clinically Localized, High Risk Prostate Cancer. European Urology, 2020, 77, 285.	0.9	0
530	Letter to the Editor re: â€œSemiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptakeâ€• Molecular Imaging and Biology, 2020, 22, 19-21.	1.3	0
531	Modes of Failure Following Metastasis Directed Therapy in Patients with Oligometastatic Hormone Sensitive Prostate Cancer: A Multi-institutional Analysis. International Journal of Radiation Oncology Biology Physics, 2020, 108, e869-e870.	0.4	0
532	Perspectives in Oncology: a new article type for Medical Oncology. Medical Oncology, 2020, 37, 21.	1.2	0
533	Hormonal Manipulation of Prostate Cancer. , 2000, , 293-311.		0
534	New Paradigms in the Management of Hormone Refractory Disease. , 2000, , 289-303.		0
535	Solid Tumors Target the HSC Niche to Establish Metastatic Footholds in the Marrow. Blood, 2008, 112, 552-552.	0.6	0
536	A Multi-targeted Approach to Treating Bone Metastases. , 2010, , 441-448.		0
537	Targeting Efferocytic M2 Monocytes and Macrophages Offers Therapeutic Promise in Prostate Cancer Skeletal Metastasis. FASEB Journal, 2015, 29, LB457.	0.2	0
538	Contemporary treatment patterns and short-term outcomes in men with very high-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 103-103.	0.8	0
539	Development of an automated and sensitive microfluidic device for circulating tumor cell (CTC) analysis and single cell capturing.. Journal of Clinical Oncology, 2016, 34, e23031-e23031.	0.8	0
540	Computer extracted nuclear features from Feulgen and H&E images to predict biochemical recurrence in prostate cancer patients following radical prostatectomy.. Journal of Clinical Oncology, 2016, 34, 5067-5067.	0.8	0

#	Article	IF	Citations
541	Computer extracted features on H&E images to improve biochemical recurrence prediction of Kattan nomogram for prostate cancer patients following radical prostatectomy: Preliminary findings.. Journal of Clinical Oncology, 2016, 34, 11556-11556.	0.8	0
542	A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).. Journal of Clinical Oncology, 2017, 35, TPS5094-TPS5094.	0.8	0
543	A secondary analysis of PSA response in NRG Oncology/RTOG 9902: A phase III trial of adjuvant chemotherapy with androgen suppression and radiation for high-risk prostate cancer (CaP).. Journal of Clinical Oncology, 2017, 35, 5078-5078.	0.8	0
544	PD60-10â€ƒA PROSPECTIVE PHASE 2/3 MULTI-CENTER STUDY OF 18 F-DCFPYL PET/CT IMAGING IN PATIENTS WITH PROSTATE CANCER â€“ EXAMINATION OF DIAGNOSTIC ACCURACY (OSPREY). Journal of Urology, 2019, 201, .	0.2	0
545	MP05-02â€ƒCTC AND CTDNA ASSAYS REVEAL COMPLIMENTARY INFORMATION FOR METASTATIC UROTHELIAL CANCER PATIENTS. Journal of Urology, 2019, 201, .	0.2	0
546	Abstract 4556: Targeting the TAM receptors on prostate cancer tumor-associated macrophages. , 2019, , .		0
547	Abstract 1383: Isolating circulating tumor cells from a large screening blood volume: A pilot study using diagnostic leukapheresis. , 2019, , .		0
548	Abstract 2360: Targeting IL-4R alpha on tumor-associated macrophages as a therapeutic strategy for prostate cancer. , 2019, , .		0
549	Feasibility of digital pathology of circulating tumor cells with morphologic analysis in localized bladder cancer.. Journal of Clinical Oncology, 2020, 38, 525-525.	0.8	0
550	Abstract 6493: Optimized methods for studies of extracellular vesicles in kidney cancer. , 2020, , .		0
551	Abstract 342: Profiling mRNAs of parental prostate cancer cells with different phenotypes and their daughter extracellular vesicles using the NanoString low RNA input nCounter assay. , 2020, , .		0
552	Abstract 5365: Profiling circulating tumor cell RNA from a large blood screening volume: A pilot study using diagnostic leukapheresis followed by the NanoString low RNA input nCounter assay. , 2020, , .		0
553	Abstract B68: NF-κB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma. , 2020, , .		0
554	PD51-03â€ƒDIGITAL PATHOLOGY OF CIRCULATING TUMOR CELLS WITH MORPHOLOGIC ANALYSIS IS FEASIBLE IN LOCALIZED BLADDER CANCER. Journal of Urology, 2020, 203, e1084.	0.2	0
555	Modeling Cancer as A Complex Adaptive System: Genetic Instability and Evolution. , 2006, , 537-556.		0
556	Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014. Reviews in Urology, 2003, 5 Suppl 2, S28-34.	0.9	0
557	Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014. Reviews in Urology, 2003, 5 Suppl 3, S45-51.	0.9	0
558	Twelve unanswered questions in cancer inspired by the life and work of Leland Chung: "if this is true, what does it imply"?. American Journal of Clinical and Experimental Urology, 2021, 9, 254-260.	0.4	0

#	Article	IF	Citations
559	720â€...CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies. , 2021, 9, A749-A749.		0
560	Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score.. Journal of Clinical Oncology, 2022, 40, 35-35.	0.8	0
561	Transcriptomic discriminators of response to apalutamide in patients with prostate cancer (PC) on active surveillance (AS).. Journal of Clinical Oncology, 2022, 40, 267-267.	0.8	0
562	Extracellular Vesicle Uptake Assay via Confocal Microscope Imaging Analysis. Journal of Visualized Experiments, 2022, , .	0.2	0
563	Abstract 1078: An immunosuppressive signature in bone marrow as a potential biomarker for recurrence of metastatic prostate cancer after prostatectomy. , 2019, , .		0
564	Abstract 1358: Tumor-derived extracellular vesicles as kidney cancer biomarkers. , 2019, , .		0
565	Abstract 3774: Elevated cancer evolution dynamics: Emergence of polyploid cancer cells in response to multimodal therapy as an adaptive response on both individual and collective levels. , 2019, , .		0
566	Abstract 4597: Bladder cancer patients experience circulating tumor cell number surge during intramedullary nailing procedures intended for treating pathological fractures. , 2019, , .		0
567	Abstract B022: The polyaneuploid transition as a hedge against failures in resistance acquisition. Cancer Research, 2022, 82, B022-B022.	0.4	0
568	Abstract IA017: The polyaneuploid cancer cell state as a mediator of therapeutic resistance. Cancer Research, 2022, 82, IA017-IA017.	0.4	0
569	Abstract A001: Modeling cancerâ€™s ecological and evolutionary dynamics. Cancer Research, 2022, 82, A001-A001.	0.4	0
570	Abstract B015: Eco-evolutionary dynamics of poly-aneuploid cancer cells: A life history model. Cancer Research, 2022, 82, B015-B015.	0.4	0